1. Generics Bulletin
  2. >>Products
  3. >>Generics

Generic Drug Cluster: What Are Global Regulators Discussing?

FDA’s Sarah Ibrahim Outlined Key Generic Drug Topics Among Seven Health Agencies

 
• By Urtė Fultinavičiūtė

In its ongoing attempt to embrace international harmonization, the US Food and Drug Administration invited stakeholders from both sides of the Atlantic to discuss how global health regulators can join forces to improve generic drug development at a recent webinar on “Expanding Generic Drug Access Through International Engagements.”

Illustration of officials at a roundtable and world map in the background
The Generic Drug Cluster has seven regulatory bodies • Source: Shutterstock

“Recognizing the interconnectedness of actions across countries, collaboration emerges as essential,” said Sarah Ibrahim, associate director for global affairs at the Office of Generic Drugs at the US Food and Drug Administration, during her introductory session on OGD’s global affairs and international engagement at a recent webinar on “Expanding Generic Drug Access Through International Engagements.”.

Ibrahim noted how harmonization and alignment of regulatory standards and requirements across global regions play a “crucial role in fostering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

CivicaScript Offers Generic Tecfidera To US Pharmacies For $47 Per Bottle

 
• By Urtė Fultinavičiūtė

As CivicaScript continues its mission to make treatments more accessible with its newly launched generic Tecfidera at a low price, generic drug coverage remains under threat, showed AAM analysis.

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment.